Pharmafile Logo
Pharmafocus logo
Advanced Search

M&A

Showing 15 posts of 45 posts found.

2016

Seven pharma trends for 2016

December 24, 2015
Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing M&A, MA, biosimilars, collaborations, digital pharma, emerging markets, patient centricity, pharma, pricing

What will be the key industry trends in 2016?Pricing pressures

Feature
labcorps_purchase_of_covance_topped_the_outsourcing_deals_in_2015

M&A activity drives record year for pharma outsourcing deals

December 11, 2015
Sales and Marketing Covance, M&A, MA, labcorp, outsourcing

A drastic increase pharma industry in M&A activity has propelled the value of pharmaceutical outsourcing deals from $9.9 billion in …

News
astrazeneca image

AstraZeneca acquires ZS Pharma for $2.7bn, announces Q3 results

November 6, 2015
Medical Communications AstraZeneca, M&A, MA, ZS Pharma, ZS-9, acquisitions, financial results, hyperkalaemia, mergers

AstraZeneca has announced its acquisition of ZS Pharma for an all-cash total of $2.7 billion. In the latest mega-money deal …

News
Shire

Shire to acquire Dyax in $5.9 billion deal

November 2, 2015
Manufacturing and Production, Research and Development, Sales and Marketing Dyax, M&A, MA, R&D, Shire, hereditary angioedema, rare disease

Shire has struck a deal to acquire the biotech firm Dyax for $5.9 billion, in order to acquire exclusive rights …

News
6127242068_23c80ef94f_z

Pharma dominates global M&A activity

July 10, 2015
Sales and Marketing M&A, MA, acquisitions, mergers, takeovers

Mergers and acquisitions in the pharma, medical and biotech sectors have hit the highest levels in nearly 15 years, a …

News
Deopmed logo

Horizon attempts a hostile $3bn Depomed takeover

July 9, 2015
Manufacturing and Production, Research and Development, Sales and Marketing Depomed, M&A, MA, acquisitions, horizon, mergers, takeover

Dublin-based specialty pharmaceutical company Horizon has launched a bid to buy Depomed for $3 billion. Horizon, a biopharma company focussed …

News
Teva image

Teva ‘to increase Mylan bid to $43bn’

July 7, 2015
Sales and Marketing M&A, MA, Mylan, Teva, generics

Israeli drugmaker Teva is considering whether to up its bid for US rival firm Mylan, with reports that it could …

News
Mylan image

Mylan tells Teva to ‘stop playing games’ and make firm bid

June 2, 2015
Manufacturing and Production, Sales and Marketing M&A, MA, Mylan, Teva, generics

Mylan has written another strongly-worded letter to Teva, this time accusing the Israeli firm of ‘playing games’ and violating US …

News
teva_copy

M&A drama continues as Mylan rejects Teva

April 28, 2015
Sales and Marketing M&A, MA, Mylan, Perrigo, Teva, bids, generics, takeovers

Mylan has firmly rejected Teva’s acquisition bid, even though its own bid for Irish firm Perrigo has also been turned …

News
talent_pipeline

Hold your horses: M&A is about talent, not just pipelines

November 25, 2013
Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing M&A, MA, mergers, molloy, roik, rsa, talent

The morning mist is rising on the battlefield. At stake: the crown riches and glory of tomorrow’s pharma leadership. The …

Feature

Pressure on pharma M&A

January 7, 2013
Research and Development, Sales and Marketing Ernst & Young, M&A, MA, mergers

The world’s largest pharma companies will be under greater pressure to merge with or purchase other firms over the next …

News

Termeer exit could help Sanofi

September 30, 2010
Sales and Marketing Genzyme, M&A, MA, Sanofi

Genzyme’s chief executive Henri Termeer has signalled he will retire next year, a move which would help smooth the way …

News

Two $1 billion dollar acquisition deals go through

August 11, 2010
Sales and Marketing Alcon, M&A, MA, Novartis, Ratiopharm, Teva

Two major acquisition deals mounted by Teva and Novartis are in their final stages as they move to complete potentially …

News
OSI Pharmaceuticals

Astellas set to acquire OSI Pharmaceuticals for $4bn

May 17, 2010
Research and Development, Sales and Marketing Astellas, M&A, MA, OSI

After four months and several failed bids Astellas Pharma has signed a definitive merger agreement with US biotech firm OSI …

News

Pharma mergers and acquisitions in 2009

December 22, 2009
Research and Development, Sales and Marketing Abbott, GSK, J&J, JJ, M&A, MA, Novartis, Pfizer, Wyeth, generics, industry, merger, year in review

This year saw two ‘mega mergers’ in the sector, the acquisition of Wyeth by Pfizer and the reverse takeover of …

Feature
The Gateway to Local Adoption Series

Latest content

Just – Evotec given Gates Foundation grant to increase global biotherapeutics access

January 8, 2026

Johnson & Johnson submits robotic surgical system for De Novo classification

January 8, 2026

EA Pharma announces phase 3 trial for new schizophrenia treatment in Japan

January 7, 2026

Eleva appoints Erich Rajkovic as Chief Business Officer

January 7, 2026

MedPharm announces US FDA inspection of North Carolina manufacturing facility

January 6, 2026